IP Library › Granted Patent US 10,806,791
Granted Patent B2
US 10,806,791 · App. 16/196,628 · Granted Oct 20, 2020

Carbohydrate conjugates as delivery agents for oligonucleotides

Inventors: Muthiah Manoharan (Cambridge, MA); Kallanthottathil G. Rajeev (Cambridge, MA); Jayaprakash Nair (Cambridge, MA); Martin Maier (Cambridge, MA)
Assignee: ALNYLAM PHARMACEUTICALS, INC.
A61K47/28A61K31/70A61K31/7004A61K31/7052A61K31/7088A61K31/713A61K47/16A61K47/22A61K47/543A61K47/549A61K47/60C07H21/02A61K48/00Y02A50/385Y02A50/411Y02A50/467Y02P20/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,806,791
App. No.
16/196,628
Granted
Oct 20, 2020
Kind
B2
Abstract

The present invention provides a phosphorothioate-modified oligonucleotide comprising a structure shown below: The present invention also provides a phosphorothioate-modified oligonucleotide comprising a structure having formula (CIII):

Claims (49)

1. A phosphorothioate-modified oligonucleotide comprising a structure shown below:

wherein:

L G is independently for each occurrence a monosaccharide carbohydrate selected from the group consisting of allose, altrose, arabinose, cladinose, erythrose, erythrulose, fructose, D-fucitol, L-fucitol, fucose, fucosamine, fuculose, galactose, D-galactosaminitol, galactosamine, N-acetyl-galactosamine (GalNAc), glucose, glucose-6- phosphate, glucosaminitol, glucosamine, N-acetyl-glucosamine (GluNAc), glucose glyceraldehyde, L-glycero-D-manno-heptose, glycerol, glycerone, gulose, idose, lyxose, mannose, mannose-6-phosphate, mannosamine, lactose, psicose, quinovose, quinovosamine, rhamnose, rhamnitol, rhamnosamine, ribose, ribulose, sedoheptulose, sorbose, tagatose, talose, tartaric acid, threose, xylose, and xylulose;

the Linker is —[(P-Q″-R) q -X-(P′-Q ′″-R′)] q″ -T-, wherein:

P, R, T, P R′, and T are each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), C(O)NH, CH 2 , CH 2 NH, CH 2 O; NHCH(R a )C(O), —C(O)—CH(R a )—NH—, CH═N—O,

or heterocyclyl;

Q″ and Q′″ are each independently for each occurrence absent, —(CH 2 ) n —, —C(R 1 )(R 2 )(CH 2 ) n— , —(CH 2 ) n C(R 1 )(R 2 )—, —(CH 2 CH 2 O) m CH 2 CH 2 —,or —(CH 2 CH 2 O) m CH 2 CH 2 NH—;

X is absent or a cleavable linking group;

R a is H or an amino acid side chain;

R 1 and R 2 are each independently for each occurrence H, CH 3 , OH, SH or N(R N ) 2 ;

R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl or benzyl;

q, q′, and q″ are each independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;

n is independently for each occurrence 1-20; and

m is independently for each occurrence 0-50; and

the oligonucleotide is modified with at least one phosphorothioate linkage.

2. The phosphorothioate-modified oligonucleotide of claim 1 , wherein the oligonucleotide is double-stranded.

3. The phosphorothioate-modified oligonucleotide of claim 1 , wherein the oligonucleotide is single-stranded.

4. The phosphorothioate-modified oligonucleotide of claim 3 , wherein the oligonucleotide is a hairpin or antisense.

5. The phosphorothioate-modified oligonucleotide of claim 1 , wherein the structure is at the 5′-end of the oligonucleotide.

6. The phosphorothioate-modified oligonucleotide of claim 1 , wherein the monosaccharide carbohydrate is galactose or N—acetylgalactosamine.

7. The phosphorothioate-modified oligonucleotide of claim 1 , wherein the phosphorothioate-modified oligonucleotide contains nucleotide sugars having a moiety at the 2′-position selected from the group consisting of 2′-H, 2′-hydroxyl, 2′-methoxyethyl, 2′OCH 3 , 2′-O-allyl, 2′-C-allyl, and 2′-fluoro.

8. A phosphorothioate-modified oligonucleotide comprising a structure having formula (CIII):

wherein:

X is O, S, NR N or CR P 2 ;

B is independently for each occurrence hydrogen, optionally substituted natural or non—natural nucleobase, optionally substituted natural nucleobase conjugated with -linker-R L or optionally substituted non-natural nucleobase conjugated with -linker-R L ;

R 1 , R 2 , R 3 , R 4 and R 5 are each independently for each occurrence H, OR 6 , F, N(R N ) 2 , or-J-linker-R L ;

J is absent, 0, S, NR N , OC(O)NH, NHC(O)O, C(O)NH, NHC(O), NHSO, NHSO 2 , NHSO 2 NH, OC(O), C(O)O, OC(O)O, NHC(O)NH, NHC(S)NH, OC(S)NH, OP(N(R P ) 2 )O, or OP(N(R P ) 2 );

R 6 is independently for each occurrence hydrogen, hydroxyl protecting group, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted alkenyl, optionally substituted heteroaryl, polyethyleneglycol (PEG), a phosphate, a diphosphate, a triphosphate, a phosphonate, a phosphonothioate, a phosphonodithioate, a phosphorothioate, a phosphorothiolate, a phosphorodithioate, a phosphorothiolothionate, a phosphodiester, a phosphotriester, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z 1 )(Z 2 )—O-nucleoside, —P(Z 1 )(Z 2 )—O-oligonucleotide, —P(Z 1 )(Z 2 )-formula (CIII), —P(Z 1 )(O-linker-R L )—O-nucleoside, —P(Z 1 )(O-linker-R L )—O-oligonucleotide, or —P(Z 1 )(O-linker-R L )-O-formula (CIII);

R N is independently for each occurrence H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted heteroaryl or an amino protecting group;

R P is independently for each occurrence occurrence H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl or optionally substituted heteroaryl;

R L is hydrogen or a ligand; and

Z 1 and Z 2 are each independently for each occurrence O, S N(alkyl) or optionally substituted alkyl;

provided that i) R 6 is a phosphorothioate at least once; and ii) R 5 is-J-linker-R L at least once, wherein R L is a ligand having the structure of

wherein L G is independently for each occurrence a monosaccharide carbohydrate selected from the group consisting of allose, altrose, arabinose, cladinose, erythrose, erythrulose, fructose, D-fucitol, L-fucitol, fucose, fucosamine, fuculose, galactose, D-galactosaminitol, galactosamine, N-acetyl-galactosamine (GalNAc), glucose, glucose-6-phosphate, glucosaminitol, glucosamine, N-acetyl-glucosamine (GluNAc), glucose glyceraldehyde, L-glycero-D-manno-heptose, glycerol, glycerone, gulose, idose, lyxose, mannose, mannose-6-phosphate, mannosamine, lactose, psicose, quinovose, quinovosamine, rhamnose, rhamnitol, rhamnosamine, ribose, ribulose, sedoheptulose, sorbose, tagatose, talose, tartaric acid, threose, xylose, and xylulose;

wherein the linker in formula (CIII) and the Linker in the structure of R L each independently is —[(P-Q″-R) q -X-(P′-Q′″-R′) q′ ] q″ -T-, wherein:

P, R, T, P′, R′, and T are each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), C(O)NH, CH 2 , CH 2 NH, CH 2 O; NHCH(R a )C(O), —C(O)—CH(R a )—NH—, CH═N-O,

or heterocyclyl;

Q″ and Q′″ are each independently for each occurrence absent, —(CH 2 ) n —, —C(R 1 )(R 2 )(CH 2 ) n —, —(CH 2 C(R 1 )(R 2 )—, —(CH 2 CH 2 O) m CH 2 CH 2 —, or —(CH 2 CH 2 O) m CH 2 CH 2 NH—;

X is absent or a cleavable linking group;

R a is H or an amino acid side chain;

R 1 and R 2 are each independently for each occurrence H, CH 3 , OH, SH or N(R N ) 2 ;

R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl or benzyl;

q, q′, and q″ are each independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;

n is independently for each occurrence 1-20; and

m is independently for each occurrence 0-50.

9. The phosphorothioate-modified oligonucleotide of claim 1 , wherein the oligonucleotide is double-stranded.

10. The phosphorothioate-modified oligonucleotide of claim 8 , wherein the oligonucleotide is single-stranded.

11. The phosphorothioate-modified oligonucleotide of claim 10 , wherein the oligonucleotide is a hairpin or antisense.

12. The phosphorothioate-modified oligonucleotide of claim 8 , wherein the monosaccharide carbohydrate is galactose or N-acetylgalactosamine.

Assignments (2)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2023
From: MANOHARAN, MUTHIAH; RAJEEV, KALLANTHOTTATHIL G.; NARAYANNAIR, JAYAPRAKASH K.; MAIER, MARTIN
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 063080/0480 →
Continuity (12)
Continuation 15817473 · Nov 20, 2017
Continuation 14835272 · Aug 25, 2015
Continuation 14329540 · Jul 11, 2014
Continuation 13693478 · Dec 4, 2012
Continuation 13326203 · Dec 14, 2011
Continuation 12328528 · Dec 4, 2008
Provisional Application 61097261 · Sep 16, 2008
Provisional Application 61091093 · Aug 22, 2008
Provisional Application 61127751 · May 14, 2008
Provisional Application 61013597 · Dec 13, 2007
Provisional Application 60992309 · Dec 4, 2007
Related Publication 20190184018A1 · Jun 20, 2019
Cited By (5)
US 50,996 US 12,258,563 US 12,258,564 US 12,472,148 US 12,508,320